FDA approves tuberculosis drugBMJ 1998; 317 doi: https://doi.org/10.1136/bmj.317.7150.11a (Published 04 July 1998) Cite this as: BMJ 1998;317:11
- Deborah Josefson
- San Francisco
The US Food and Drug Administration has approved rifapentine (Priftin)—the first new antituberculosis drug to be licensed in 25 years.
Rifapentine is indicated for pulmonary tuberculosis but must be used in conjunction with other antituberculosis drugs. It is expected to increase patient compliance because it has a shorter treatment course than conventional drugs.
Current treatment …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial